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Background: Because the natural history of primary Raynaud phenomenon (RP) is unclear, we undertook this long-term
(14 years) follow-up of an epidemiologic study on RP to investigate the incidence, remittance rate, and transition rate
toward systemic sclerosis and other scleroderma spectrum disorders in a population-based sample of subjects.
Methods: In 1988 and 1989, 296 subjects obtained from a random sample of the general population of the Alpine valley
of Tarentaise (southeast France) completed a cross-sectional study on RP. Of these, 78 met the diagnostic criteria for RP
(RP). From April 2002 to March 2003, we were able to get follow-up information on 292 people (dropout rate, 1.4%).
Eighteen subjects (6.1%) had died, and the remaining 274 were successfully contacted. They were first evaluated by a
standardized phone interview regarding their cold sensitivity, digital color changes, and RP. If any significant medical
changes related to RP and/or suggesting scleroderma were reported, these subjects were invited for a medical evaluation.
Results:Mortality was similar in RP and RP subjects, and no death was due to an RP-related condition. Seven cases of
new RP were diagnosed in the RP group, which corresponds to an annual incidence rate of 0.25%. Among the 72 RP
subjects and the 7 subjects with a new RP available for follow-up, none developed clinical features of scleroderma. A
disappearance of RP attacks for 2 winters or more was reported by 24 RP subjects (33%).
Conclusions: These results show that, in the general population, RP is most often a benign condition and may disappear
in a substantial proportion of subjects. ( J Vasc Surg 2006;44:1023-8.)Raynaud phenomenon (RP) is a frequent (90%) and
early manifestation in systemic sclerosis (systemic sclero-
derma). Several follow-up studies of clinical series of pri-
mary RP patients have shown a substantial annual incidence
(0.8%-6.7%) of connective tissue diseases (CTDs), most of
which were systemic sclerosis and mixed CTD.1-16
RP is quite common in the general population, with a
prevalence ranging from 3% to 21%,17-25 and it is usually
thought to be mainly an idiopathic and benign condition.
The recent community-based study of the Framingham
offspring did not report any incident case of CTD after a
7-year follow-up of 128 RP subjects, and it even found an
unexpected remittance rate of 64%, which was never de-
scribed before.26 The question of the natural history of RP
in subjects from the general population remains, therefore,
wide open.
We had the opportunity to perform the follow-up
evaluation of a sample of the general population of the
Alpine valley of Tarentaise (southeast France), which we
From the Centre de Recherche Universitaire, La Léchère,a Clinique de
Médecine Vasculaire, Centre Hospitalier Universitaire, Grenoble,b and
Division of Rheumatology and Immunology, Department of Medicine,
Medical University of South Carolina.c
Supported by National Institutes of Health grant AR-31283 from the
National Institute of Arthritis and Musculoskeletal Diseases, the Univer-
sité Joseph Fourier–Grenoble I, France, the Association des Scléroder-
miques de France, and the District of Aigueblanche (Savoie, France).
Competition of interest: none.
Reprint requests: Patrick H. Carpentier, MD, Centre de Recherche Universita-
ire, 73260 La Léchère, France (e-mail: patrick.carpentier@ujf-grenoble.fr).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.07.037had investigated 14 years earlier for the prevalence and
etiology of RP.20,22 We undertook this work with three
objectives: to evaluate the incidence and the remittance rate
of RP in the general population and to assess its transition
rate toward systemic sclerosis and scleroderma spectrum
disorders.
SUBJECTS AND METHODS
Summary of the 1988-1989 study
This study was performed as a long-term follow-up of
subjects who had participated in our epidemiologic study of
RP. The methods used in this survey were previously de-
scribed in detail20,22 and are summarized here.
Phase I: phone survey screening. Random samples
from households of Tarentaise, a cold Alpine valley in the
southeast of France, were obtained from telephone lists.
Every subject aged 18 years or more and living in the selected
households was included in the survey until the planned
sample size of 2000 subjects was reached. The subjects were
interviewed by phone (phase I) about demographic and
socioeconomic data and the occurrence of symptoms in the
hands suggesting RP. This was based on two key questions:
1. Are your fingers unusually sensitive to cold? (Q)
2. Do your fingers sometimes show unusual color chan-
ges? (C)
Subjects were classified asQCwhen they answered yes
to either question and QC when both answers were no.
All QC subjects and a random sample of QC cases were
invited to a face-to-face interview and medical examination
(phase II), where the final diagnosis was made.
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medical interview made the diagnosis of RP through a
standardized color chart–assisted diagnostic procedure that
has been previously validated.19 A thorough questionnaire
about general medical history, occupation, and lifestyle was
also completed. In addition, a clinical examination was
performed, including the evaluation of other vascular ac-
rosyndromes, the search for signs of CTDs, and nailfold
capillary microscopy.1,27 A total of 296 subjects partici-
pated in this phase of the survey. They were classified as
RP (n 78) or RP (n 218) according to the result of
the standardized diagnostic procedure for RP. RP sub-
jects were further classified as follows.
1. Primary RP (n  56) patients with no sign of CTD, no
clinical arterial or neurologic abnormalities in the upper
limbs, no history of local trauma or frostbite, no treat-
ment with any drug known for inducing RP, no expo-
sure to vibration or repeated occupational trauma of the
hands, and a normal nailfold capillary microscopy.
2. Secondary RP (n  22), which included the following.
A. Systemic sclerosis and other scleroderma spectrum
disorders, ie, CREST syndrome, mixed CTD sys-
temic sclerosis sine scleroderma,27 and overlap syn-
dromes with clinical features of scleroderma, were
searched for by systematic careful clinical and capil-
laroscopic examinations1,27 and by biological and/
or instrumental tests when needed. However, none
was found during the initial survey.
B. Vibration white finger (n  8) was diagnosed when
the subject had been significantly exposed to a hand-
held vibrating tool (total operating time 1000
hours) with a topography of RP consistent with the
use of the tool.
C. Hypothenar hammer syndrome (n  6) was diag-
nosed when there was a significant exposure to
repeated occupational trauma of the handmore than
once a day for at least 10 years with a positive clinical
Allen test (showing impaired function of the ulnar or
the superficial palmar arcade arteries) and a homo-
lateral RP. Two subjects met the criteria for both
vibration white finger and hypothenar hammer syn-
drome.
D. Miscellaneous RP (n  10) included subjects with
RP not meeting the criteria of the above-mentioned
categories.
Follow-up evaluation
From April 2002 to March 2003, every participant in
phase II of the initial survey was asked to answer a phone
questionnaire derived from the initial one with supplemen-
tal questions regarding the evolution of their condition:
worsening or disappearance of cold sensitivity and color
changes, occurrence of digital ulcerations, hardening of the
skin in the hands or fingers, and a newly made diagnosis of
RP or scleroderma by a physician.
If any significant medical changes related to RP were
detected in the standardized questionnaire (new occur-rence, worsening or disappearance of RP, associated skin
changes, or arthritis), a second phone interview was per-
formed by an experienced vascular physician in a nonstand-
ardized fashion to confirm the information from the first
phone call and obtain additional and more detailed data. In
case of suspected disappearance of RP, the complete ab-
sence of RP attacks for at least two winters was double-
checked, and we also investigated for how long the subject
was free of them andwhether there were noticeable circum-
stances related to this disappearance.When a worsening (ie,
increasing severity and/or frequency of attacks) or new
onset RP was likely or if any change consistent with a
possible CTDwas suspected, the subject was invited to a new
face-to-face interview that used the samediagnostic procedure
for RP as in the initial survey and a medical examination that
included careful examination of the hands and capillary mi-
croscopy.20,22 In case of death, the cause of death and the
presence or absence of diagnosed scleroderma were evaluated
with the help of the relatives and the family doctor.
Statistical analysis
Analyses were performed with SPSS software (version
13.0 for Windows; SPSS Inc, Chicago, Ill). The Fisher
exact test and 2 test were used for categorical data, and
Mann-Whitney and Wilcoxon tests were used for evaluat-
ing relationship between categorical and quantitative/ordinal
variables. Survival analysis was performed with the Kaplan-
Meier method, and comparisons of survival rates used the
log-rank test. A P value of .05 was considered significant.
RESULTS
Raynaud status at follow-up. From April 2002 to
March 2003,wewere able to get in touchwith 274of the 296
original subjects. The flow chart is summarized in Fig 1. Four
subjects (1.4%; 1 RP and 3 RP) had dropped out, and 18
Fig 1. Flow chart of the 296 subjects in the follow-up. RP,
Raynaud phenomenon.(6.1%; 5 RP subjects [6.4%] and 13 RP [6.0%]; not
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respectively, 70.2  6.3 years and 71.0  3.6 years in the
RP and RP groups (not significant), and death was
mainly related to cardiovascular diseases (44%) or cancer
(33%) in both groups; no death was related to an RP-
associated condition.
None of the remaining subjects reported that a new
diagnosis of RP, systemic sclerosis, or any scleroderma
spectrum disorders had beenmade by a physician, and none
had observed any suggestive skin changes. Twenty-eight of
the 202 subjects with no RP in 1988-1989 complained
about some pallor of the fingers in 2002-2003, but only 7
met the criteria for RP, corresponding to an annual inci-
dence rate of 0.25% (95% confidence interval, 0.17%-
0.33%; 0.24% in women and 0.26% in men).
Eight of the 72 RP subjects reported a worsening of
their RP attacks that was confirmed in 3 when comparing
the initial and final frequency rate, duration, and topo-
graphic extent of the attacks (Fig 1). Sixteen subjects
(including the three subjects with worsened RP and the
seven with new-onset RP) had a medical examination.
None presented a clinical or capillaroscopic picture sug-
gesting scleroderma. The potential explanations for the
changes in RP status after careful examination are listed in
Tables I and II.
Twenty-four of the 72 subjects initially with RP were
no longer experiencing attacks for at least the 2 last winters,
and in 20 of them, the time since RP disappearance was
more than 5 years. The associated conditions initially found
in these subjects who are likely to have definitively recov-
ered fromRP and the timing and events that they described
Table I. Associated conditions in worsened RP
Patient
No. Sex
Year of
birth
Classification
in 1988-1989
133 F 1925 Primary RP R
448 F 1954 Primary RP M
1986 M 1927 VWF I
RP, Raynaud phenomenon; VWF, Vibration white finger.
Table II. Associated conditions in subjects with a new RP
Patient
No. Sex
Year of
birth
Conditions possibly associated with RP
onset
237 M 1963 Vibration white finger : exposure
14,000 h
308 M 1909 None
592 F 1946 Hypertension: new -blocker treatment
668 F 1959 Primary RP in several members of the
family
835 F 1935 Hypertension: new -blocker treatment
1104 M 1967 Left arm trauma with severe nerve
damage (homolateral RP)
1498 F 1928 Rheumatoid arthritis diagnosed in 1970
RP, Raynaud phenomenon.as related with RP disappearance are listed in Table III.Only four subjects reported a treatment that could have
influenced RP; two moved to a warmer region but did not
believe that it was related to their improvement.
Disappearance rate of RP and predictors of recovery.
The disappearance rate of RP, based on the subjects’ inter-
views, is illustrated in Fig 2. It is similar in men and women,
with almost a linear pattern and a slope approximating 3%
per year.
Our efforts to find predictors of recovery did not show
any statistically significant relationship with the following:
1. There was no link with the initial severity of attacks
(attack rate during the winter, number of fingers in-
volved, or number of phalanges involved per finger),
nor with the age of the subject, the age at RP onset, or
the duration of RP.
2. The disappearance rate was similar in subjects with
primary and secondary RP (Table IV). Patients initially
diagnosed as having acrocyanosis associated with their
RP might have a higher remission rate (8 of 14 subjects
vs 16 of 58 nonacrocyanotic patients), but this did not
reach statistical significance (P  .056).
DISCUSSION
This study shows three main findings: (1) We found a
relatively low incidence of new-onset RP of 0.25% per year,
with no sex-related difference. (2) Even after 14 years of
follow-up, we did not find any RP subject with initially
negative screening for systemic sclerosis and scleroderma
spectrum disorders who had developed such a condition.
(3) A substantial minority of RP subjects (one third)
showed prolonged remission and probably had recovered
from their RP.
We feel confident that these results are reliable, because
we had a very low rate of dropout (1.4% after 14 years), and
the phone and face-to-face interview procedures used in
this study were validated in previous work.20,22 Indeed,
every RP subject not meeting the diagnostic criteria for
RP at the follow-up interview acknowledged that he/she
had experienced such attacks in the past and was able to say
for how long they did not occur. Not every RP subject
had a medical examination in this follow-up study; how-
ever, all those with worsening of RP or new-onset RP were
examined. None of the others reported a new diagnosis of
systemic sclerosis or scleroderma spectrum disorder or
complained of digital ulceration or hardening of skin of the
hands when specifically asked about these problems. Be-
pe of worsening
Conditions possibly associated with RP
worsening
hand worse Carpal tunnel syndrome of right hand
fingers involved Homolateral nocturnal paresthesia
sed frequency rate Increased exposure to vibrationTy
ight
ore
ncreacause the Tarentaise valley is part of a regional scleroderma
bratio
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been listed in this register.
Wewere expecting a higher incidence rate of new-onset
RP and a predominance of women, in accordance with the
high prevalence (16.5%) and sex differences we previously
found in the Tarentaise cross-sectional study. However,
only adults were included in our study, and 42.5% of our
RP Tarentaise subjects reported an early onset of RP
(before the age of 20 years): the incidence measured in adults
Table III. Associated conditions and circumstances of RP
Patient
No. Sex
RP-associated conditions and
acrosyndromes noted in the
initial survey
458 M HHS  VWF (2500 h)
842 M HHS, thoracic outlet syndrome
1209 M VWF (15,000 h)
1669 M None
1748 M HHS
1823 M HHS; chilblains
226 F Chilblains
252 F None
265 F None
342 F None
710 F Acrocyanosis
711 F None
858 F None
952 F None
988 F Acrocyanosis; CTS
1036 F Acrocyanosis
1118 F None
1177 F None
1225 F None
1275 F Acrocyanosis
1286 F None
1747 F None
1890 F Acrocyanosis; chilblains
1968 F Acrocyanosis
RP, Raynaud phenomenon; HHS, hypothenar hammer syndrome; VWF, vi
*Moved to a warmer region, but thinks it was not related to improvement.
Fig 2. Time course of disappearance of Raynaud phenomenon
(RP) in the 72 RP subjects during the follow-up.only is thus not representative of the entire population.Regarding the development of systemic sclerosis and
scleroderma spectrum disorder in RP subjects, we could
not find any such transition in the 72 contacted RP
subjects nor in the 7 new-onset RP subjects nor in the
medical records of the 5 deceased RP subjects. The only
RP subject we were unable to get follow-up information
about was a 28-year-old man with primary RP and a history
of RP and chilblains already acknowledged at the age of
ppearance in 24 subjects
Age at
last RP
attack (y)
Events associated with the
end of RP according to
subject’s report
Years
since last
RP attack
49 None 11
35 Sympathectomy 12
62 None 10
58 None 5
60 Retirement 12
61 Retirement 5
28 None* 11
30 None 8
49 None 9
50 None 8
60 None 9
30 Spa treatment 6
51 None 10
28 None 7
32 None 13
48 None 7
45 AntiHT treatment 3
53 CTS operation 10
49 None* 13
24 Pregnancy 8
33 Pregnancy 3
30 None 13
60 Retirement 8
45 None 7
n white finger; AntiHT, antihypertensive; CTS, carpal tunnel syndrome.
Table IV. Recovery of Raynaud phenomenon (RP)
according to the initial classification (N  72)
Classification n (%) Resolved RP, n (%)
Primary RP* 52 (72.2%) 17 (33%)
Secondary RP 20 (27.8%) 7 (35%)
Vibration white finger† 6‡ (7.0%) 2‡ (33%)
HHS§ 6‡ (8.3%) 4‡ (67%)
Miscellaneous 9 (12.5%) 2 (22%)
HHS, Hypothenar hammer syndrome.
*No sign of connective tissue disease, no clinical arterial or neurologic
abnormalities in the upper limbs, no history of local trauma or frostbite, no
treatment with a drug known for inducing RP, no exposure to vibration or
repeated occupational trauma of the hands, and normal nailfold capillary
microscopy.
†Exposure (total operating time) to a handheld vibrating tool1000 hours
with topography of RP consistent with the use of the tool.
‡One subject with RP recovery validated the criteria for both vibration white
finger and hypothenar hammer syndrome.
§Exposure to repeated professional trauma of the handmore than once a day
for at least 10 years with positive Allen test and homolateral RP.disa7 years. He refused the idea of a follow-up during the
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mation for further contact: his dropout is independent of
the study aim, and the evolution toward a CTD after a
history of primary RP of more than 20 years is very unlikely.
Although it was not the primary aim of their study, such
transition was not reported either by Suter et al26 in their
community-based longitudinal study. This contrasts with
the reports from studies performed in RP subjects followed
up in referral medical centers specialized in CTD,1-16 which
show a mean incidence rate of developing CTD of 1.75%
per year in patients with a first negative screening at the
study onset.14 However, these studies included selected
patients: even those who were screened negative by clinical
and capillaroscopic examination at a referral medical center
are probably not comparable to the primary RP from a
random sample from the general population (in Tarentaise,
50% of our RP subjects never had consulted a physician for
their RP). Our negative result (none in 1008 patient-years)
leads to an estimated incidence of RP-related CTD lower
than 0.2 per 100 patient-years, according to Poisson’s law
with a 95% confidence interval. Because the prevalence of
RP in Tarentaise is 16.5%, this would mean an incidence
rate of RP-related CTD lower than 330 per million inhab-
itants per year; an annual incidence of 1.75% in RP subjects
would have given an incidence rate of 2900 per million
inhabitants per year, which is inconsistent with the data
from the literature.28
The disappearance rate of RP is usually considered low.
Among the 16 longitudinal studies mentioned previously,1-16
only Williams et al15 mentioned 2 remissions, but they
studied selected patients. By contrast, Suter et al26 reported
a remittence rate of 64% after a 7 years’ follow-up in their
community-based study. Our data also show a substantial
rate of 33% after 14 years, the difference being probably
explained partially by the more restrictive criteria we used
for defining disappearance. We think from our time-course
data that the rate of 3% per year is a realistic estimate. We
found similar resolving rates in occupational RP, which,
this time, is in accordance with the literature.29,30 Our
attempt to find predictive factors for such a disappearance
failed. The decrease in vascular reactivity with age might be
a part of the answer, but the explanation of such a remit-
tance is quite unclear and would deserve longitudinal phys-
iological studies in RP subjects.
CONCLUSIONS
This long-term (14 years) follow-up study of a
population-based sample of subjects with RP and RP-
negative controls clearly shows that in most subjects, RP is
a benign condition because (1) we could not find a single
case of incident CTDs in the 72 RP subjects after an initial
negative clinical and capillaroscopic screening, which gives
a transition rate lower than 0.2%, and (2) RP can disappear
in as many as one third of subjects within this time period.
However, because RP is most often the first sign of systemic
sclerosis and precedes it by many years, it remains impor-
tant to screen for possible early scleroderma. These results
contrast with those of hospital series of patients, illustratingthat the epidemiologic approach in population-based sam-
ples of subjects is important for a better understanding of
the clinical significance of a non–life-threatening condition
such as RP.
The authors thank Christiane Féchoz for her participa-
tion in performing the interviews and express their deep
appreciation to Corine Trolliet for a fantastic tracking of
the subjects.
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